Novel Long-acting Bronchodilators for COPD and Asthma

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2008 Jul 8

PMID 18604231

Citations 37

Authors

M Cazzola

M G Matera

Affiliations

Soon will be listed here.

Abstract

An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control. Therefore, the incorporation of once-daily dose administration is an important strategy to improve adherence and is a regimen preferred by most patients, which may also lead to enhancement of compliance, and may have advantages leading to improved overall clinical outcomes. Once-daily beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as carmoterol, indacaterol, GSK-159797, GSK-597901, GSK-159802, GSK-642444 and GSK-678007 are under development for the treatment of asthma and COPD. Also some new long-acting antimuscarinic agents (LAMAs) such as aclidinium, LAS-35201, GSK656398, GSK233705, NVA-237 (glycopyrrolate) and OrM3 are under development. In any case, the current opinion is that it will be advantageous to develop inhalers containing combination of several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimens as much as possible. Consequently, several options for once-daily dual-action ultra LABA+LAMA combination products are currently being evaluated. A different approach is to have a dimer molecule in which both pharmacologies are present (these molecules are known as M3 antagonist-beta2 agonist (MABA) bronchodilators). The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products.

Citing Articles

Pharmacokinetics of pulmonary indacaterol in rat lung using molecular imprinting solid-phase extraction coupled with RP-UPLC.

Tarek M, Ghoniem N, Hegazy M, Wagdy H Sci Rep. 2024; 14(1):23126.

PMID: 39366999 PMC: 11452728. DOI: 10.1038/s41598-024-72822-0.

The Saudi initiative for asthma - 2024 update: Guidelines for the diagnosis and management of asthma in adults and children.

Al-Moamary M, Alhaider S, Allehebi R, Idrees M, Zeitouni M, Al Ghobain M Ann Thorac Med. 2024; 19(1):1-55.

PMID: 38444991 PMC: 10911239. DOI: 10.4103/atm.atm_248_23.

Stability-indicating UPLC assay coupled with mass spectrometry for the analysis of vilanterol degradation products in human urine.

Tarek M, Wagdy H, Hegazy M, Ghoniem N Sci Rep. 2024; 14(1):2439.

PMID: 38286793 PMC: 10824719. DOI: 10.1038/s41598-024-52664-6.

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor.

Buigues P, Gehrke S, Badaoui M, Dudas B, Mandana G, Qi T J Chem Theory Comput. 2023; 19(15):5260-5272.

PMID: 37458730 PMC: 10413856. DOI: 10.1021/acs.jctc.3c00023.

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children.

Al-Moamary M, Alhaider S, Alangari A, Idrees M, Zeitouni M, Al Ghobain M Ann Thorac Med. 2021; 16(1):4-56.

PMID: 33680125 PMC: 7908897. DOI: 10.4103/atm.ATM_697_20.

References

Martinez F . Safety of long-acting beta-agonists--an urgent need to clear the air. N Engl J Med. 2005; 353(25):2637-9. DOI: 10.1056/NEJMp058299. View

Rossoni G, Manfredi B, Razzetti R, Civelli M, Berti F . Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther. 2006; 20(3):250-7. DOI: 10.1016/j.pupt.2006.01.004. View

Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View

Yang W, Martinot J, Pohunek P, Beier J, Magula D, Cameron R . Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol. 2008; 99(6):555-61. DOI: 10.1016/S1081-1206(10)60386-9. View

Singh D, Brooks J, Hagan G, Cahn A, OConnor B . Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63(7):592-8. DOI: 10.1136/thx.2007.087213. View

Sturton R, Trifilieff A, Nicholson A, Barnes P . Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2007; 324(1):270-5. DOI: 10.1124/jpet.107.129296. View

Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S . Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2007; 102(1):50-6. DOI: 10.1016/j.rmed.2007.08.003. View

Rabe K, Timmer W, Sagkriotis A, Viel K . Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008; 134(2):255-262. DOI: 10.1378/chest.07-2138. View

Chuchalin A, Tsoi A, Richter K, Krug N, Dahl R, Luursema P . Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med. 2007; 101(10):2065-75. DOI: 10.1016/j.rmed.2007.06.002. View

10.

Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, DUrzo A . A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008; 102(7):1033-44. DOI: 10.1016/j.rmed.2008.02.001. View

11.

Campbell L . Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs. 2000; 58 Suppl 4:25-33; discussion 52. DOI: 10.2165/00003495-199958004-00004. View

12.

Brookman L, Knowles L, Barbier M, Elharrar B, Fuhr R, Pascoe S . Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin. 2007; 23(12):3113-22. DOI: 10.1185/030079907X242863. View

13.

Laforce C, Alexander M, Deckelmann R, Fabbri L, Aisanov Z, Cameron R . Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy. 2007; 63(1):103-11. DOI: 10.1111/j.1398-9995.2007.01555.x. View

14.

Fitzgerald M, Fox J . Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today. 2007; 12(11-12):472-8. DOI: 10.1016/j.drudis.2007.04.003. View

15.

Rossoni G, Manfredi B, Razzetti R, Civelli M, Bongrani S, Berti F . Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol. 2005; 144(3):422-9. PMC: 1576020. DOI: 10.1038/sj.bjp.0706096. View

16.

Bateman E, Hurd S, Barnes P, Bousquet J, Drazen J, Fitzgerald J . Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1):143-78. DOI: 10.1183/09031936.00138707. View

17.

Kikkawa H, Naito K, Ikezawa K . Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol. 1991; 57(2):175-85. DOI: 10.1254/jjp.57.175. View

18.

Claxton A, Cramer J, Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-310. DOI: 10.1016/s0149-2918(01)80109-0. View

19.

Bender B . Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002; 109(6 Suppl):S554-9. DOI: 10.1067/mai.2002.124570. View

20.

Barnes P . The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2005; 117 Suppl 12A:24S-32S. DOI: 10.1016/j.amjmed.2004.10.018. View